231 related articles for article (PubMed ID: 21366638)
1. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy.
Zelinkova Z; de Haar C; de Ridder L; Pierik MJ; Kuipers EJ; Peppelenbosch MP; van der Woude CJ
Aliment Pharmacol Ther; 2011 May; 33(9):1053-8. PubMed ID: 21366638
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.
Bortlik M; Machkova N; Duricova D; Malickova K; Hrdlicka L; Lukas M; Kohout P; Shonova O; Lukas M
Scand J Gastroenterol; 2013 Aug; 48(8):951-8. PubMed ID: 23834232
[TBL] [Abstract][Full Text] [Related]
3. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
[TBL] [Abstract][Full Text] [Related]
4. Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type.
Kanis SL; de Lima-Karagiannis A; van der Ent C; Rizopoulos D; van der Woude CJ
J Crohns Colitis; 2018 Jul; 12(8):939-947. PubMed ID: 29771301
[TBL] [Abstract][Full Text] [Related]
5. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.
Steenholdt C; Svenson M; Bendtzen K; Thomsen OØ; Brynskov J; Ainsworth MA
Aliment Pharmacol Ther; 2011 Jul; 34(1):51-8. PubMed ID: 21535447
[TBL] [Abstract][Full Text] [Related]
6. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
Casanova MJ; Chaparro M; Domènech E; Barreiro-de Acosta M; Bermejo F; Iglesias E; Gomollón F; Rodrigo L; Calvet X; Esteve M; García-Planella E; García-López S; Taxonera C; Calvo M; López M; Ginard D; Gómez-García M; Garrido E; Pérez-Calle JL; Beltrán B; Piqueras M; Saro C; Botella B; Dueñas C; Ponferrada A; Mañosa M; García-Sánchez V; Maté J; Gisbert JP
Am J Gastroenterol; 2013 Mar; 108(3):433-40. PubMed ID: 23318480
[TBL] [Abstract][Full Text] [Related]
7. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
Reddy JG; Loftus EV
Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
[TBL] [Abstract][Full Text] [Related]
8. A Narrative Review on Anti-Tumor Necrosis Factor α Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact.
Roseira J; Ramos J
Acta Med Port; 2019 Apr; 32(4):305-312. PubMed ID: 31067425
[TBL] [Abstract][Full Text] [Related]
9. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.
Miehsler W; Novacek G; Wenzl H; Vogelsang H; Knoflach P; Kaser A; Dejaco C; Petritsch W; Kapitan M; Maier H; Graninger W; Tilg H; Reinisch W;
J Crohns Colitis; 2010 Sep; 4(3):221-56. PubMed ID: 21122513
[TBL] [Abstract][Full Text] [Related]
10. Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis.
Kiely CJ; Subramaniam K; Platten J; Pavli P
Intern Med J; 2016 May; 46(5):616-9. PubMed ID: 27170239
[TBL] [Abstract][Full Text] [Related]
11. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease.
Gisbert JP; Chaparro M
Am J Gastroenterol; 2013 Sep; 108(9):1426-38. PubMed ID: 23752881
[TBL] [Abstract][Full Text] [Related]
12. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.
Mahadevan U; Wolf DC; Dubinsky M; Cortot A; Lee SD; Siegel CA; Ullman T; Glover S; Valentine JF; Rubin DT; Miller J; Abreu MT
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):286-92; quiz e24. PubMed ID: 23200982
[TBL] [Abstract][Full Text] [Related]
13. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety.
de Lima A; Zelinkova Z; van der Ent C; Steegers EA; van der Woude CJ
Gut; 2016 Aug; 65(8):1261-8. PubMed ID: 25966992
[TBL] [Abstract][Full Text] [Related]
14. Infliximab in ulcerative colitis.
Aberra FN; Lichtenstein GR
Gastroenterol Clin North Am; 2006 Dec; 35(4):821-36. PubMed ID: 17129815
[TBL] [Abstract][Full Text] [Related]
15. Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception.
O'Donnell S; O'Morain C
Aliment Pharmacol Ther; 2008 May; 27(10):885-94. PubMed ID: 18284649
[TBL] [Abstract][Full Text] [Related]
16. Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system.
Wieringa JW; Driessen GJ; Van Der Woude CJ
Expert Rev Gastroenterol Hepatol; 2018 Aug; 12(8):811-818. PubMed ID: 29972674
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
Danese S
Dig Liver Dis; 2008 Jul; 40 Suppl 2():S225-8. PubMed ID: 18598993
[TBL] [Abstract][Full Text] [Related]
18. Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review.
El Mourabet M; El-Hachem S; Harrison JR; Binion DG
Curr Drug Targets; 2010 Feb; 11(2):234-41. PubMed ID: 19916950
[TBL] [Abstract][Full Text] [Related]
19. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.
Khan N; Asim H; Lichtenstein GR
Expert Opin Drug Saf; 2014 Dec; 13(12):1699-708. PubMed ID: 25406728
[TBL] [Abstract][Full Text] [Related]
20. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
Ebert EC; Das KM; Mehta V; Rezac C
Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]